羚锐制药(600285.SH)：前三季度净利润6.51亿元，同比增长13.43%

Core Viewpoint - Lingrui Pharmaceutical (600285.SH) reported a year-on-year increase in revenue and net profit for the first three quarters of 2025, indicating positive financial performance [1] Financial Performance - The total operating revenue for the first three quarters reached 3.041 billion yuan, representing a year-on-year growth of 10.23% [1] - The net profit attributable to shareholders of the parent company was 651 million yuan, showing a year-on-year increase of 13.43% [1] - The basic earnings per share were 1.148 yuan [1]